Beyond Injections: Surgery Still Outperforms Medication

GLP-1 receptor agonists (GLP-1 RAs) like semaglutide and tirzepatide have dominated the weight loss conversation over the last few years. Formulated to suppress appetite, regulate blood sugar, and promote satiety, they mimic a hormone naturally produced in the gut. For many, these weekly injections appear to promise something that felt out of reach for years: meaningful, measurable progress on the scale.

But long before injections became popular, surgical approaches like the sleeve gastrectomy and gastric bypass were delivering not just weight loss, but remission of obesity-related conditions like diabetes, sleep apnea, and hypertension.

The excitement around medications has renewed interest in the seriousness of treating obesity, but it’s important to remember that surgery remains the gold standard for lasting metabolic health and weight management for those who are severely overweight.

What’s the Real Deal?

GLP-1 RAs work by enhancing signals that help the brain recognize fullness and by slowing the rate food leaves the stomach. They help the body mimic part of the gut’s natural rhythm, reducing hunger and improving insulin sensitivity. But when treatment stops, these effects often fade, and weight regain can follow. For many, long-term success depends on continued injections and careful dose management.

Bariatric surgery, by contrast, reshapes the internal pathways that influence hunger and metabolism. Procedures such as the sleeve gastrectomy not only reduce stomach size but also alter hormonal responses involved in appetite, glucose regulation, and fat storage. These changes create a metabolic environment that supports sustained weight loss and often improves or resolves conditions like type 2 diabetes.

Bariatric surgery is also a diving board for a mental reboot. The behavioral transformation that takes place helps people reconnect with hunger cues and make more mindful food choices; where medication acts like a dimmer switch for appetite, surgery rewires the circuit.

The path to sustained weight loss is different for everyone. Multiple factors are involved, and the best approach depends on body mass index (BMI), medical history, and personal goals.

GLP-1 therapy may be better suited for people who:

• Have mild to moderate obesity
• Are not surgical candidates
• Prefer to start with a less invasive treatment
• Are managing early-stage metabolic concerns such as prediabetes
• Can commit to regular injections and long-term medical supervision

GLP-1 medications can serve as a useful bridge toward better health and, in some cases, as a stepping-stone to surgery.

Bariatric surgery, on the other hand, is for individuals who:

• Meet clinical guidelines for BMI or health criteria
• Have struggled with obesity despite diet and medication
• Are ready for a more permanent and comprehensive solution
• Want to reduce dependence on pharmacologic therapy

As far as outcomes go, bariatric surgery outperforms GLP-1 RAs.¹ In a real-world review of electronic medical records, researchers analyzed over 50,000 cases. They found that sleeve gastrectomy and gastric bypass were linked to roughly five times more total weight loss than weekly injections of semaglutide or tirzepatide at the two-year mark. They also noted that while clinical trials often show promising results for GLP-1 RAs, actual outcomes tend to be lower, even among patients who maintained their prescriptions for a full year.²

Yet, despite clear differences in each therapy, keep in mind that the matter of “either-or” is not that stark. It goes back to personal goals, health indicators, provider-led education, and medical support. In fact, some patients benefit from both surgery and pharmacology, using GLP-1 therapy to jump-start initial weight loss before surgery, or to support maintenance afterward under medical guidance.

Whichever route you choose, sustainable results come from a combination of medical treatment, nutrition, activity, and emotional support. Bariatric programs often integrate these elements through a multidisciplinary team, something medications alone can’t replicate.

A Quick Cost Analysis

Obesity also affects finances, both for individuals and for society. In 2016 alone, medical costs related to obesity in the United States totaled an estimated $260.6 billion³, reflecting the wide-ranging impact of obesity-related conditions such as diabetes, hypertension, and cardiovascular disease. The cost for individuals managing obesity often come in two forms: ongoing medical expenses and long-term treatment costs for associated conditions.

An extensive cohort study of over 30,000 U.S. patients resulted in a striking comparison between GLP-1 receptor agonist therapy and metabolic bariatric surgery (MBS): during the initial six months, costs for patients in both groups were similar, with medical and pharmacy costs averaging around $1,600 per month.³ Then, over the following two years, the patterns diverged: patients using GLP-1 medications saw total monthly costs remain elevated, largely due to ongoing pharmacy expenses. By contrast, the bariatric surgery group experienced higher costs initially, driven by the short-term expense of the surgery itself, but by the second year, total monthly costs had dropped significantly. Summed over the two-year period, the study found mean total costs of $63,483 for GLP-1 therapy versus $51,794 for bariatric surgery, translating to average savings of nearly $12,000 for surgical patients.³

These findings reinforce a broader point: for patients with a high BMI and obesity-related health risks, bariatric surgery is as much a medically transformative intervention as it is economically advantageous.

What Should You Do?

Both GLP-1 therapy and bariatric surgery are valid, effective approaches to managing obesity, and neither is “wrong” or a sign of failure. The ultimate goal is improved health, better energy, and a reduced risk of obesity-related conditions.

For patients who have struggled with weight despite diets, medications, or lifestyle changes, bariatric surgery may offer the most transformative and healthful results. It provides a comprehensive, lasting approach to weight loss and metabolic health while reducing the need for ongoing pharmacologic therapy. At the same time, GLP-1 therapy can be a powerful tool, either as a first step or as part of a combined strategy.

If you’re ready to explore what’s possible, consulting with a bariatric specialist is the (most effective) next step. At the Gastric Sleeve Center, our team walks patients through evaluation and procedure planning, and provides long-term follow-up. Reach out today to schedule your consultation, ask questions, and formulate a plan that fits your goals and lifestyle.

¹Barrett, T. S., Hafermann, J. O., Richards, S., LeJeune, K., & Eid, G. M. (2025). Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists. JAMA surgery, e253590. Advance online publication. https://doi.org/10.1001/jamasurg.2025.3590.

²American Society for Metabolic and Bariatric Surgery. (2025, June 17). Head-to-head Study Shows Bariatric Surgery Superior to GLP-1 Drugs for Weight Loss. American Society for Metabolic and Bariatric Surgery. https://asmbs.org/news_releases/head-to-head-study-shows-bariatric-surgery-superior-to-glp-1-drugs-for-weight-loss/.

³Barrett, T. S., Hafermann, J. O., Richards, S., LeJeune, K., & Eid, G. M. (2025). Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists. JAMA surgery, e253590. Advance online publication. https://doi.org/10.1001/jamasurg.2025.3590.